Sumitomo Dainippon Pharma Annual Report 2017
80/102

(A) Methods of determining fair value of nancial instruments, and matters related to securities and derivative transactionsAssets(1) Cash and time deposits The fair value of time deposits is approximately equal to book value.(2) Trade notes, (3) Trade accounts, (4) Due from parent company, unconsolidated subsidiaries and afliates The fair value of these assets due within a year is approximately equal to book value.(5) Marketable securities and investment securitiesThe fair value of equity securities with fair value is based on the quoted market price. The fair value of bonds is based on the price offered by the corresponding nancial institutions. The fair value of negotiable certicates of deposit is approximately equal to book value. See Note 2 (c), “Summary of Signicant Accounting Policies — Marketable and Investment Securities” for notes related to securities according to the purpose for which they are held.Liabilities(1) Trade notes, (2) Trade accounts, (3) Due to parent company, unconsolidated subsidiaries and afliates, (4) Short-term loans payable, (5) Income taxes payable The fair value of these liabilities due within a year is approximately equal to book value.(6) Bonds payableThe fair value of corporate bonds is calculated according to market price.(7) Long-term loans payable The fair value of long-term loans payable is calculated as the present value of the total sum of principal and interest discounted using an assumed rate that would have been applicable has a new identical loan been undertaken.Derivative transactions See note 7 on “Derivative Transactions.”(B) Financial instruments for which the ascertainment of a fair value is deemed to be exceedingly difcult and are not included in “(5) Marketable securities and investment securities” are as follows:Notes to Consolidated Financial StatementsSumitomo Dainippon Pharma Co., Ltd. and Consolidated SubsidiariesYears Ended March 31, 2017 and 2016Financial SectionThe fair value of unlisted shares and investment in unconsolidated subsidiaries and afliates is not disclosed given the unavailability of quoted market prices because they are deemed to be exceedingly difcult to ascertain.The fair value of investment in limited partnerships is not disclosed as their assets consist of those deemed to be exceedingly difcult to ascertain, such as unlisted shares.Amount on consolidated balance sheet$ 56,69716,6709,223¥ 6,3551,819614¥ 6,3501,8671,033Unlisted sharesInvestment in unconsolidated subsidiaries and afliatesInvestment in limited partnershipMillions of yenThousands ofU.S. dollars201620172017Sumitomo Dainippon Pharma Co., Ltd. Annual Report 201779

元のページ  ../index.html#80

このブックを見る